Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of ZL-1211 in CLDN18.2-positive unresectable or metastatic solid tumors
CTR20220646Phase 2Active
- Sponsor
- Regen Biopharma (Suzhou)
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ZL-1211 in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic cancer (PC), sponsored by Regen Biopharma (Suzhou). Started Jul 2022; status: active.
02
Drugs
ZL-1211
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20220646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220646.